Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma.

Wu, Zhicheng; Wang, Qiu; Liu, Xiuqing; Zheng, Jiantong; Ji, Ling; Li, Xiaofeng

Wu, Zhicheng; Wang, Qiu; Liu, Xiuqing; Zheng, Jiantong; Ji, Ling; Li, Xiaofeng.

Afiliação

Wu Z; Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China.
Wang Q; Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China.
Liu X; Department of Laboratory Medicine, Shenzhen Second People's Hospital, Shenzhen, China.
Zheng J; Shenzhen Dymind Biotechnology Company Limited, Shenzhen, China.
Ji L; Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China.
Li X; Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China.

J Oncol ; 2022: 8998493, 2022.

Article em En | MEDLINE | ID: mdl-36281289

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google